ARCA biopharma sells legacy Gencaro and rNAPc2 assets to Genvara for $300K

Oruka Therapeutics, Inc.

ARCA entered Asset Purchase Agreement with Genvara Biopharma to sell all rights in Gencaro (bucindolol) for atrial fibrillation and rNAPc2 (AB201) for COVID-19.
Total cash consideration is $300,000, payable pre-closing and held in escrow until the Closing.
Closing of asset sale is automatic immediately following the First Merger (Oruka merger).
Buyer Genvara is controlled by Dr. Michael Bristow, ARCA's former President/CEO.
The asset sale is a condition to the broader reverse merger with Oruka Therapeutics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.